Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted) (2011 - 2025)
Supernus Pharmaceuticals (SUPN) reported EPS (Weighted Average and Diluted) of -$0.07 for Q4 2025, down 125.93% year-over-year from $0.27 in Q4 2024, and up 91.25% quarter-over-quarter from -$0.8 in Q3 2025.
Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted) (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 15 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.07 in Q4 2025.
- EPS (Weighted Average and Diluted) for Q4 2025 came in at -$0.07, down 125.93% year-over-year; the trailing twelve-month figure through Dec 2025 was -$0.68 (down 151.52% YoY), and the FY2025 annual result was -$0.68, down 151.52% from the prior year.
- EPS (Weighted Average and Diluted) improved to -$0.07 in Q4 2025 per SUPN's latest filing, from -$0.8 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.69 in Q3 2024 and troughed at -$0.8 in Q3 2025.
- A 5-year average of $0.13 and a median of $0.12 in 2021 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) jumped 1900.0% in 2024, then tumbled 9520.64% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.04 in 2021, then soared by 950.0% to $0.42 in 2022, then sank by 95.24% to $0.02 in 2023, then soared by 1250.0% to $0.27 in 2024, then slumped by 125.93% to -$0.07 in 2025.
- Business Quant data shows SUPN's EPS (Weighted Average and Diluted) at -$0.07 in Q4 2025, -$0.8 in Q3 2025, and $0.4 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | Supernus Pharmaceuticals | 2.63 Bn | 2.24 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.07 |
| Sep 30, 2025 | -0.80 |
| Jun 30, 2025 | 0.40 |
| Mar 31, 2025 | -0.21 |
| Dec 31, 2024 | 0.27 |
| Sep 30, 2024 | 0.69 |
| Jun 30, 2024 | 0.36 |
| Mar 31, 2024 | 0.00 |
| Dec 31, 2023 | 0.02 |
| Sep 30, 2023 | -0.29 |
| Jun 30, 2023 | -0.02 |
| Mar 31, 2023 | 0.29 |
| Dec 31, 2022 | 0.42 |
| Sep 30, 2022 | 0.03 |
| Jun 30, 2022 | 0.14 |
| Mar 31, 2022 | 0.43 |
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.40 |
| Jun 30, 2021 | 0.43 |
| Mar 31, 2021 | 0.11 |